Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular - Summary - MDSpire

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • By

  • Steven E. Nissen

  • Kathy Wolski

  • David D’Alessio

  • Govinda Weerakkody

  • Jacek Kiljanski

  • Russell J. Wiese

  • Imre Pavo

  • Bertrand Cariou

  • Stephen J. Nicholls

  • June 1, 2026

  • 0 min

Share

Objective:

To evaluate the association of tirzepatide and dulaglutide with outcomes for an expanded 6-component composite cardiorenal end point.

Approach:
    Key Findings:
    • Tirzepatide was noninferior to dulaglutide for the 3-component composite end point of cardiovascular death, MI, or stroke.
    Interpretation:

    Limitations:
    • The analysis was a post hoc evaluation.
    • The trial's primary end point was limited to a 3-component composite.
    Conclusion:

    The study compares the cardiorenal effects of tirzepatide and dulaglutide in diabetic patients with cardiovascular conditions.

Original Source(s)

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls

  • June 1, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Lung ultrasound B-lines, NT-proBNP, and left atrial volume Index for bedside characterization of preserved-ejection-fraction phenotype in acute heart failure: a single-center observational study

Acute aortic regurgitation due to aortic valve leaflet injury during percutaneous coronary intervention: a case report